[go: up one dir, main page]

HUP9800573A2 - Orálisan beadható rapamicintartalmú készítmények és eljárás előállításukra - Google Patents

Orálisan beadható rapamicintartalmú készítmények és eljárás előállításukra

Info

Publication number
HUP9800573A2
HUP9800573A2 HU9800573A HUP9800573A HUP9800573A2 HU P9800573 A2 HUP9800573 A2 HU P9800573A2 HU 9800573 A HU9800573 A HU 9800573A HU P9800573 A HUP9800573 A HU P9800573A HU P9800573 A2 HUP9800573 A2 HU P9800573A2
Authority
HU
Hungary
Prior art keywords
preparation
oral administration
rapamycin
rapamycin formulations
formulations
Prior art date
Application number
HU9800573A
Other languages
English (en)
Inventor
Arwinder Singh Nagi
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of HU9800573D0 publication Critical patent/HU9800573D0/hu
Publication of HUP9800573A2 publication Critical patent/HUP9800573A2/hu
Publication of HUP9800573A3 publication Critical patent/HUP9800573A3/hu
Publication of HU224701B1 publication Critical patent/HU224701B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

NCS = (57) A találmány magból és cűkőrbevőnatból állórapamicintartalmú, szilárd dózisegységre vőnatkőzik, ahől acűkőrbevőnat rapamicint, egy vagy több, felületmódősító hatásúanyagőt, egy vagy többféle cűkrőt és adőtt esetben egy vagy többkötőanyagőt tartalmaz. A találmány kiterjed a fenti készítményekelőállítására is. ŕ
HU9800573A 1997-03-14 1998-03-13 Rapamycin formulations for oral administration and process for their preparation HU224701B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81501597A 1997-03-14 1997-03-14

Publications (4)

Publication Number Publication Date
HU9800573D0 HU9800573D0 (en) 1998-05-28
HUP9800573A2 true HUP9800573A2 (hu) 1999-06-28
HUP9800573A3 HUP9800573A3 (en) 2000-01-28
HU224701B1 HU224701B1 (en) 2006-01-30

Family

ID=25216622

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800573A HU224701B1 (en) 1997-03-14 1998-03-13 Rapamycin formulations for oral administration and process for their preparation

Country Status (25)

Country Link
EP (1) EP0868911B1 (hu)
JP (2) JP4616426B2 (hu)
KR (1) KR100513919B1 (hu)
CN (1) CN1140268C (hu)
AR (1) AR012069A1 (hu)
AT (1) ATE223705T1 (hu)
AU (1) AU723943B2 (hu)
BR (1) BR9801120B1 (hu)
CA (1) CA2230748C (hu)
CY (1) CY2313B1 (hu)
CZ (1) CZ292949B6 (hu)
DE (1) DE69807768T2 (hu)
DK (1) DK0868911T3 (hu)
ES (1) ES2183287T3 (hu)
HK (1) HK1015677A1 (hu)
HU (1) HU224701B1 (hu)
IL (1) IL123525A (hu)
NZ (1) NZ329976A (hu)
PT (1) PT868911E (hu)
RU (1) RU2220714C2 (hu)
SG (1) SG63824A1 (hu)
SI (1) SI0868911T1 (hu)
TW (1) TW550091B (hu)
UA (1) UA56143C2 (hu)
ZA (1) ZA982112B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
TW574040B (en) * 1997-06-13 2004-02-01 Wyeth Corp Rapamycin formulations for oral administration
JP4969747B2 (ja) * 2001-01-19 2012-07-04 武田薬品工業株式会社 錠剤フィルムコーティング用組成物
NZ538781A (en) * 2002-09-17 2007-11-30 Wyeth Corp Oral formulations
EP1858511A1 (en) * 2005-03-08 2007-11-28 LifeCycle Pharma A/S Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
EP2086514A2 (en) * 2006-09-26 2009-08-12 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
CN101583349A (zh) * 2006-11-07 2009-11-18 惠氏公司 糖衣及其所用的方法
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
KR20180058659A (ko) 2015-05-20 2018-06-01 노파르티스 아게 에베롤리무스와 닥톨리십의 약제학적 병용물
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110585159B (zh) * 2019-09-12 2021-11-02 杭州华东医药集团新药研究院有限公司 一种含有西罗莫司的片剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK0525960T3 (da) * 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
GB2278780B (en) * 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.

Also Published As

Publication number Publication date
CZ292949B6 (cs) 2004-01-14
CA2230748A1 (en) 1998-09-14
CZ77198A3 (cs) 1998-09-16
NZ329976A (en) 1999-10-28
UA56143C2 (uk) 2003-05-15
IL123525A0 (en) 1998-10-30
AU723943B2 (en) 2000-09-07
DK0868911T3 (da) 2003-01-20
DE69807768T2 (de) 2003-02-06
CY2313B1 (en) 2003-11-14
HU9800573D0 (en) 1998-05-28
DE69807768D1 (de) 2002-10-17
HK1015677A1 (en) 1999-10-22
RU2220714C2 (ru) 2004-01-10
AU5838398A (en) 1998-09-17
SG63824A1 (en) 1999-03-30
CA2230748C (en) 2010-08-03
JPH10259131A (ja) 1998-09-29
KR19980080222A (ko) 1998-11-25
AR012069A1 (es) 2000-09-27
PT868911E (pt) 2002-12-31
EP0868911B1 (en) 2002-09-11
IL123525A (en) 2002-03-10
BR9801120A (pt) 2000-01-11
SI0868911T1 (en) 2002-12-31
EP0868911A2 (en) 1998-10-07
CN1197639A (zh) 1998-11-04
HU224701B1 (en) 2006-01-30
JP4616426B2 (ja) 2011-01-19
KR100513919B1 (ko) 2006-02-28
JP2009298823A (ja) 2009-12-24
HUP9800573A3 (en) 2000-01-28
TW550091B (en) 2003-09-01
BR9801120B1 (pt) 2009-12-01
ATE223705T1 (de) 2002-09-15
EP0868911A3 (en) 2000-12-06
ZA982112B (en) 1999-09-13
ES2183287T3 (es) 2003-03-16
CN1140268C (zh) 2004-03-03

Similar Documents

Publication Publication Date Title
HUP9800573A2 (hu) Orálisan beadható rapamicintartalmú készítmények és eljárás előállításukra
AU5278096A (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
BG104620A (en) Oral pharmaceutical extended release dosage form
DE3750431D1 (de) Stabilisiertes Arzneimittel und dessen Herstellung.
DE69701532D1 (de) Orale zusammensetzung gegen zahnbelag
HK1017895A1 (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
NO976084L (no) Ny, stabil legemiddeltilberedning for dannelse av drivgassfrie aerosoler
IS1918B (is) Lyfjablöndur úr sýruóstöðugum efnum til inntöku um munn
ATE243516T1 (de) Amoxicillin und clavulanat enthaltende arzneizubereitungen
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
HUP9904065A2 (hu) Olanzapint tartalmazó bevonatos gyógyszerkészítmények
FI894476A0 (fi) Uusia kosmeettisia koostumuksia, jotka sisältävät uutetta Cichorium intybus L:n ilmaosista, ja niiden valmistus
ES2035979T3 (es) Procedimiento para la obtencion de preparaciones medicinales de efecto prolongado para dihidropiridinas.
GR3033591T3 (en) Novel taxoids, preparation thereof, and pharmaceutical compositions containing same
GR3034203T3 (en) Novel taxoids, preparation thereof, and pharmaceutical compositions containing same
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
FI955238L (fi) Uudet 5-(aryylioksimetyyli)oksatsoliinit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
HUP9900863A3 (en) 4,4-(disubstituted)cyclohexan-1-ol derivatives pharmaceutical compositions containing these compounds and use thereof
AU1180897A (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
DE69611546D1 (de) Herstellung von 2,6-dimethylnaphthalin
FR2707492B1 (fr) Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
NO880775D0 (no) Kosmetisk haarpreparat, samt fremgangsmaate for fremstilling av et slikt.
NO991740L (no) Farmas°ytiske og kosmetiske formuleringer med antimikrobiell aktivitet
AU692956C (en) Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20051123